Funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors

The time from identifying a drug target to a new drug approval is often measured in decades and can take even longer for therapies to treat rare diseases. In fact, 95% of rare diseases do not have a specific therapy approved at all. Coordinated efforts to augment the drug development pipeline along...

Descripción completa

Detalles Bibliográficos
Autores principales: La Rosa, Salvatore, Browder, Vidya, Bakker, Annette C, Blakeley, Jaishri O, Verma, Sharad K, Wong, Ling M, Morris, Jill, Bora, Naba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949486/
https://www.ncbi.nlm.nih.gov/pubmed/31793149
http://dx.doi.org/10.15252/emmm.201911656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949486/
https://www.ncbi.nlm.nih.gov/pubmed/31793149
http://dx.doi.org/10.15252/emmm.201911656

Ejemplares similares